Clinical efficacy and safety of a new 1000-mg suspension versus twice-daily 500-mg tablets of MPFF in patients with symptomatic chronic venous disorders: a randomized controlled trial
INTERNATIONAL ANGIOLOGY, vol.36, no.5, pp.402-409, 2017 (SCI-Expanded, Scopus)
- Publication Type: Article / Article
- Volume: 36 Issue: 5
- Publication Date: 2017
- Doi Number: 10.23736/s0392-9590.17.03801-9
- Journal Name: INTERNATIONAL ANGIOLOGY
- Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
- Page Numbers: pp.402-409
- Istanbul University Affiliated: No
Abstract
BACKGROUND: Chronic venous disorders (CVD) is estimated to affect 30% to 50% of women and 10% to 30% of men. The most widely prescribed treatment for CVD worldwide is micronized purified flavonoid fraction 500 mg (MPFF). The aim of this clinical trial was to develop a new once daily 1000-mg oral suspension of MPFF.